TCRT - מכפיל מחיר להכנסות עתידי alaunos.com

Alaunos Therapeutics (TCRT) is developing innovative TCR-T cancer therapies, leveraging clinic partnerships to support R&D and cash flows. The firm's forward P/S, where the current parameter is 583.70, highlights liquidity decline risks amid US export bans to Asia. Restructuring and the suspension of key programs have severely weakened competitive advantages, leaving only limited patent value.

The assessment of the margin of safety for Alaunos Therapeutics (TCRT) is based on the ratio of market capitalization to expected revenue, which determines the value of each unit of future sales. Analyzing the company's projected P/S chart, an investor can see the balance between growth potential and the risk of a price collapse due to a high cash burn rate and the threats of clinical trial suspensions for its cell therapy.